- Alzheimer’s disease
- Parkinson’s disease
- Amyotrophic Lateral Sclerosis
- Schizophrenia
- Depression
- Bipolar disorder
For each indication, Neurogenomics
and Neurotherapeutic Strategies providesin-depth analysis of the following: -Discovery projects, preclinical studies, and early-stage
human trials. -Investigational methods, including novel tools and
platforms such as animal
models, molecular imaging, and biomarkers. -Proposed mechanisms of action, pathways, and targets
that research teams
are exploring in order to move one step closer to developing
effective
therapeutics. The complexity of CNS diseases
make this area a challenging but potentially very rewarding
area for research. CNS
disorders affect a vast patient population and represent
a huge area of unmet therapeutic
need. In the United States alone, Alzheimer ’s
disease (AD), Parkinson’s disease (PD), and amyotrophic
lateral sclerosis (ALS) afflict more than 6.5 million
people. Drug discovery efforts for the most prevalent
CNS diseases have met with varying success; it is estimated
that billions of dollars are spent every year on prescription
drug sales, however, many current therapies merely
treat the symptoms but do not provide cures. Neurogenomics
and Neurotherapeutic Strategies provides insightful evaluation of the latest R&D
developments and their potential to revolutionize treatment.
About the Author Deborah Janssen has over ten years experience in the pharmaceutical industry, both as a researcher and, most recently, as the Senior Editor of Genomics & Proteomics and Drug Discovery & Development for Reed Business Information. Before her tenure at RBI, Deb spent eight years first as a research pharmacologist with Abbott Laboratories where she won the Drug Discovery Innovator Award and then as a research geneticist for Pharmacia Corp. Ms. Janssen has published a variety of scientific papers on such topics as the effects of rosiglitazone on glucose transporter regulation, macrolide-based nonpeptide antagonists of GnRH, and the in vivo blockade of dexamethasone-induced thymolysis in adrenalectomized rats. Deb holds a Master’s degree in Cell and Molecular Biology from Northeastern Illinois University and is a principal partner with Janssen Consulting. | 
